Soteira CEO Larry Jasinski is no stranger to adversity.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this Halloween, make sure you’re still in the know with MassDevice +3.
Venipuncture – drawing blood or establishing an intravenous feed – is the most common invasive medical procedure. For many patients, it’s a painful exercise in frustration when clinicians struggle to find a blood vessel, sometimes requiring multiple needle sticks.
AccuVein and CEO Ron Goldman aim to change all that with the company’s AV300 vascular illumination device. The wireless, handheld module uses a pair of lasers to paint a patient’s arm with light, making otherwise invisible or hard-to-find blood vessels apparent to the naked eye.
Neuronetics’ NeuroStar TMS therapy system
Neuronetics Inc. is paving the way for a new type of depression therapy, a non-invasive electromagnetic field treatment designed to stimulate brain cells linked to depression.
Bruce Shook, co-founder, president & CEO, talked to MassDevice about pioneering the market for the only FDA-cleared transcranial magnetic stimulation system to date, his company’s NeuroStar TMS system.
The therapy, which won the FDA nod in 2008, is a rarity in the med-tech world: A device-based approach to a psychiatric disorder.
Calypso Medical Technologies Inc. treated its 10,000th prostate cancer patient with GPS for the Body in May, an important landmark for the Seattle-based targeted radiation therapy company and its flagship device.
GPS for the Body won FDA clearance in 2006 for focused prostate cancer radiation therapy using a proprietary guidance system that tracks a tumor in real time as the body moves, keeping the radiation beam on target.
Dr. Patrick Mooney took an interesting path to the top seat at Echo Therapeutics Inc. (OTC:ECTE), a Philadelphia, Pa.-based company developing a non-invasive, wireless, transdermal continuous glucose monitoring device for the diabetes market.
Sagentia is a company that thrives on complexity. Its business is built around helping both established and emerging technology companies avoid the uncertainties of innovation.
"We operate best where there is a complex scientific or technical problem that needs resolving as part of product development,” CEO Brent Hudson told MassDevice.
Hudson, who joined the research and development consulting firm in 2009, describes the services they offer as having a little ‘r’ and a big ‘D.’